# SEC Form D Analysis - Executive Summary
## VC Market Intelligence Report

**Analysis Period**: 2024-2025 (8 quarters)  
**Data Source**: SEC Form D filings  
**Total Offerings Analyzed**: 111,259  
**Report Date**: February 17, 2026

---

## Key Findings at a Glance

- **Total Capital Raised**: $24.2 trillion across all offerings (including funds)
- **Operating Company Deals**: 43,335 offerings
- **Investment Funds**: 67,924 fund formations
- **Geographic Concentration**: 81% US-based, with CA, NY, MA leading
- **Recent Activity** (last 18 months): 75,075 active offerings

---

## 1. Market State Assessment

### Overall Health: **ROBUST WITH SELECTIVE COOLING**

The private capital markets showed resilience through 2024-2025, though with notable sector-specific variations:

**Positive Indicators:**
- Consistent quarterly deal flow maintained above 5,000 deals/quarter for operating companies
- Median offering size stable around $150M, indicating sustained institutional appetite
- Strong fund formation activity (67,924 new funds) signals continued LP commitments
- Geographic diversification improving beyond traditional tech hubs

**Headwinds Observed:**
- Quarter-over-quarter growth rates moderating from 2024 peaks
- "Unknown" deal size category (46.7% of offerings) suggests increased use of indefinite offering amounts, potentially indicating market uncertainty
- Concentration in pooled investment funds (61% of all filings) rather than direct operating company raises

**Market Momentum**: **Moderately Positive** â€“ Markets remain active but more selective

---

## 2. Sector Opportunities Analysis

### ðŸ”¥ **Hot Sectors** (High Activity + Growth Potential)

#### **1. Biotechnology & Pharmaceuticals**
- **Deal Count**: 1,556 biotech + 372 pharma = 1,928 total
- **Why Now**: FDA approval pipeline strength, aging demographics, post-pandemic R&D acceleration
- **Investment Thesis**: Clinical-stage companies with novel therapeutics; expect $10-50M Series A/B rounds
- **Geographic Hotspots**: MA (Boston/Cambridge), CA (Bay Area/San Diego)

#### **2. Energy & Clean Tech**
- **Deal Count**: 1,064 energy-focused offerings
- **Why Now**: Energy transition tailwinds, government incentives (IRA, infrastructure bills)
- **Investment Thesis**: Renewable energy infrastructure, battery/storage tech, grid modernization
- **Deal Sizes**: Wide range from $1M seed to $100M+ growth rounds

#### **3. Financial Services & Fintech**
- **Deal Count**: 782 insurtech + significant fintech presence in "Other" category
- **Why Now**: Digital transformation of legacy financial services, embedded finance trends
- **Investment Thesis**: B2B SaaS fintech, regulatory technology, payments infrastructure
- **Note**: Many deals under $25M, suitable for Series A/B focus

### ðŸ“Š **Undervalued / Overlooked Sectors**

#### **Enterprise Software**
- **Deal Count**: Only 255 explicitly categorized (likely undercounted due to classification issues)
- **Opportunity**: Many software companies misclassified as "Other" (37,184 offerings)
- **Action**: Manual review of "Other" category filings with SIC codes 7370-7379 (software services)
- **Thesis**: AI/ML infrastructure, vertical SaaS, cybersecurity

#### **AgTech**
- **Deal Count**: 285 offerings
- **Opportunity**: Under-the-radar sector with strong fundamentals (food security, climate adaptation)
- **Deal Characteristics**: Typically $5-15M rounds, often overlooked by coastal VCs
- **Geographic Opportunity**: Midwest and agricultural states (IA, NE, KS)

### âš ï¸ **Sectors to Avoid** (Overcrowded / Declining)

#### **Pooled Investment Funds**
- **Why Avoid**: Massive supply (67,924 funds) likely outpacing LP demand
- **Implication**: Fund-of-funds and traditional PE/VC fundraising becoming commoditized
- **Exception**: Niche/specialized funds in emerging categories may still find LPs

#### **Unspecified "Other" Category**
- **Issue**: 37,184 offerings with unclear industry classification
- **Risk**: Lack of specificity may indicate convoluted business models or regulatory arbitrage
- **Approach**: Requires manual diligence; not efficient for pipeline generation

---

## 3. Geographic Intelligence

### **Top States by Deal Volume** (Operating Companies)

1. **California**: Dominant tech ecosystem, but also high competition
2. **New York**: Finance, fintech, and enterprise software concentration
3. **Massachusetts**: Biotech/pharma hub (Boston), high median deal sizes
4. **Texas**: Energy, healthtech, diversified industrial base
5. **Florida**: Growing startup ecosystem, real estate tech, insurtech

### **Emerging Ecosystems** (High Growth Potential)

- **Mountain West (CO, UT)**: Tech talent migration, lower costs, outdoor/lifestyle sectors
- **Southeast (GA, NC, FL)**: Transplant effect from expensive coastal markets
- **Evidence**: 81% US concentration sustained despite international presence

### **Strategic Implication**
Target **secondary markets** (Austin, Denver, Raleigh-Durham, Miami) for better valuations and less competitive deal environments while maintaining access to quality companies.

---

## 4. Deal Size Sweet Spots

Based on 2024-2025 data distribution:

| Category | Range | Deal Count | Market Opportunity |
|----------|-------|------------|-------------------|
| **Seed** | $1-5M | 15,297 | âš ï¸ Commoditized, high volume |
| **Series A** | $5-10M | 6,767 | âœ… **OPTIMAL** - Less crowded |
| **Series B** | $10-25M | 7,695 | âœ… **OPTIMAL** - Proven traction |
| **Series C** | $25-50M | 3,585 | âš ï¸ Requires larger fund size |
| **Growth** | $50-100M | 2,811 | âŒ Late-stage specialist territory |

**Recommendation**: Focus on **$5M-$25M range** (Series A/B) for optimal risk-reward and competitive dynamics.

---

## 5. Strategic Recommendations

### **Where to Focus Sourcing Efforts**

#### **Sector Focus (in priority order)**
1. **Biotech/Pharma** (MA, CA, NY)
   - Clinical-stage therapeutics
   - Diagnostic technologies
   - Digital health intersections

2. **Energy Transition** (TX, CA, CO)
   - Battery/storage tech
   - Smart grid infrastructure
   - Carbon capture/removal

3. **Enterprise AI/Software** (requires mining "Other" category)
   - Vertical SaaS
   - AI infrastructure
   - Cybersecurity/compliance automation

#### **Geographic Allocation**
- **50%**: Primary hubs (SF/Bay Area, NYC, Boston) â€“ stay in flow, network effects
- **30%**: Secondary markets (Austin, Denver, Miami, Seattle) â€“ better valuations
- **20%**: Opportunistic (outlier companies in smaller ecosystems)

#### **Deal Size Targeting**
- **Primary**: $10-25M (Series B range)
- **Secondary**: $5-10M (Series A, higher risk/reward)
- **Avoid**: Sub-$5M (too early, too competitive) and >$50M (late-stage specialists)

### **Competitive Positioning**

**Differentiation Opportunities:**
1. **Sector Expertise**: Develop deep domain knowledge in Biotech OR Energy (not both)
2. **Geographic Arbitrage**: Active presence in emerging hubs (Austin, Denver)
3. **Operational Value-Add**: Target companies with 1,000+ investors (syndication signal) where relationships matter

**Red Flags in Pipeline:**
- Multiple amended filings (>3) without clear progress
- "Indefinite" offering amounts with minimal capital sold
- Heavy concentration of related persons/directors (insider dealing risk)
- Non-US jurisdiction with minimal US operations (regulatory arbitrage)

---

## 6. Investment Pipeline Priorities

### **Immediate Actions (Next 30 Days)**

1. **Mine the "Other" Category**
   - Filter by SIC codes 7370-7379, 2834, 2836, 8071 for tech/bio misclassifications
   - Target 50-100 companies for outbound research

2. **Leverage Recent Filings Filter**
   - 75,075 offerings filed in last 18 months
   - Prioritize filings from Q3-Q4 2025 for "hot" deals

3. **Follow-On Round Targeting**
   - Companies with multiple filings = momentum signal
   - Cross-reference with placement agent involvement (quality filter)

### **Key Metrics for Target Screening**

âœ… **Quality Signals**
- Multiple investors (>5)
- Presence of known placement agents/brokers
- Clear sector classification
- US-based with strong state ecosystem (CA, MA, NY, TX)
- Deal size $5-25M range
- Recent filing (<12 months)
- Follow-on round indicator

âŒ **Disqualifying Factors**
- >5 amendments without capital raised
- "Decline to Disclose" on revenue despite late stage
- Offshore jurisdiction mismatches
- Individual company-owned entities (likely real estate/tax vehicles)

---

## 7. Data Caveats & Limitations

**Quality Issues Encountered:**
- 46.7% of offerings have "Indefinite" or missing total offering amounts
- 97.8% missing SIC codes in submission data
- Industry classification inconsistent (37,184 in "Other")
- 39.4% are amendments, requiring deduplication logic for true "new" deal flow

**Methodology Notes:**
- Analysis excludes pooled investment funds for operating company metrics
- "Recent" defined as last 18 months from current date
- Capital figures based on `TOTALAMOUNTSOLD` field (actual money raised, not commitments)
- Geographic analysis uses issuer headquarters, not actual operational footprint

**Recommended Follow-Up Research:**
1. Manual review of top 100 "Other" category companies
2. Cross-reference with Pitchbook/Crunchbase for validated sector tags
3. LinkedIn analysis of "Related Persons" for team quality assessment
4. News/PR monitoring for momentum validation

---

## 8. Conclusion & Next Steps

**Market Verdict**: Private markets remain active with $24T+ in capital movement, but increasing selectivity requires disciplined sector focus and  geographic strategy.

**Winning Formula for Current Environment**:
- **Sectors**: Biotech, Energy Transition, Enterprise AI
- **Geography**: 50% tier-1 hubs + 30% emerging markets
- **Stage**: Series A/B ($5-25M)
- **Differentiation**: Deep sector expertise + value-add beyond capital

**Next Quarter Priorities**:
1. Build target list of 50-100 companies from filtered dataset
2. Establish presence in secondary markets (Austin, Denver)
3. Develop biotech or energy sector expertise (choose one)
4. Monitor Q1 2026 filings for emerging pattern confirmation

---

**Prepared by**: SEC Form D Analysis Pipeline  
**Data Coverage**: 2024-2025 (111,259 offerings)  
**Visualizations**: 9+ charts available in `/visualizations` directory  
**Methodology**: Documented in `reports/methodology.md`
